We confirmed the overexpression of LBH in glioblastoma, stomach, and liver cancers, and its underexpression in lung cancer, consistent with previous reports [15–19, 22], expanding prognostic and molecular insight into LBH dysregulation in these cancers. Here, LBH is linked to lung carcinoma.